The AT(N) framework for Alzheimer's disease in adults with Down syndrome.
Alzheimer's disease
Down syndrome
biomarkers
Journal
Alzheimer's & dementia (Amsterdam, Netherlands)
ISSN: 2352-8729
Titre abrégé: Alzheimers Dement (Amst)
Pays: United States
ID NLM: 101654604
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
04
2020
accepted:
04
06
2020
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
3
11
2020
Statut:
epublish
Résumé
The National Institute on Aging in conjunction with the Alzheimer's Association (NIA-AA) recently proposed a biological framework for defining the Alzheimer's disease (AD) continuum. This new framework is based upon the key AD biomarkers (amyloid, tau, neurodegeneration, AT[N]) instead of clinical symptoms and represents the latest understanding that the pathological processes underlying AD begin decades before the manifestation of symptoms. By using these same biomarkers, individuals with Down syndrome (DS), who are genetically predisposed to developing AD, can also be placed more precisely along the AD continuum. The A/T(N) framework is therefore thought to provide an objective manner by which to select and enrich samples for clinical trials. This new framework is highly flexible and allows the addition of newly confirmed AD biomarkers into the existing AT(N) groups. As biomarkers for other pathological processes are validated, they can also be added to the AT(N) classification scheme, which will allow for better characterization and staging of AD in DS. These biological classifications can then be merged with clinical staging for an examination of factors that impact the biological and clinical progression of the disease. Here, we leverage previously published guidelines for the AT(N) framework to generate such a plan for AD among adults with DS.
Identifiants
pubmed: 33134477
doi: 10.1002/dad2.12062
pii: DAD212062
pmc: PMC7588820
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12062Subventions
Organisme : Medical Research Council
ID : MR/R024901/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S011277/1
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : R01 HD064993
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG068054
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066462
Pays : United States
Informations de copyright
© 2020 the Alzheimer's Association.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest that are relevant for this manuscript.
Références
Cortex. 2015 Dec;73:36-61
pubmed: 26343344
Lancet Neurol. 2018 Oct;17(10):860-869
pubmed: 30172624
Res Dev Disabil. 2014 Oct;35(10):2267-77
pubmed: 24950014
Alzheimers Dement (N Y). 2018 Dec 13;4:703-713
pubmed: 30581976
Alzheimers Dement (Amst). 2017 May 23;9:1-9
pubmed: 28603769
J Alzheimers Dis. 2018;61(2):631-644
pubmed: 29254096
Neuropathol Appl Neurobiol. 1989 Jul-Aug;15(4):317-29
pubmed: 2528701
Nat Rev Neurosci. 2015 Sep;16(9):564-74
pubmed: 26243569
Neurology. 2019 Oct 22;93(17):e1647-e1659
pubmed: 31371569
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Int J Geriatr Psychiatry. 2015 Aug;30(8):857-63
pubmed: 25363568
Curr Alzheimer Res. 2016;13(1):30-4
pubmed: 26391049
Ann Neurol. 1998 Mar;43(3):380-3
pubmed: 9506555
Neurosci Lett. 2009 Feb 20;451(2):162-4
pubmed: 19111900
Am J Med Genet B Neuropsychiatr Genet. 2012 Jul;159B(5):598-604
pubmed: 22592955
Ann Neurol. 1985 Mar;17(3):278-82
pubmed: 3158266
J Alzheimers Dis. 2011;23(3):399-409
pubmed: 21116050
Nat Rev Drug Discov. 2012 Sep;11(9):655-6
pubmed: 22935789
Alzheimers Dement (Amst). 2020 Apr 05;12(1):e12028
pubmed: 32258359
CNS Drugs. 2019 Feb;33(2):99-106
pubmed: 30560544
Histopathology. 1988 Aug;13(2):125-37
pubmed: 2971602
Geriatrics (Basel). 2018 Jun;3(2):
pubmed: 29805967
Front Aging Neurosci. 2018 Jun 21;10:191
pubmed: 29977201
Neuromolecular Med. 2014 Jun;16(2):510-6
pubmed: 24740518
Neuropsychol Rev. 2017 Mar;27(1):31-45
pubmed: 28289920
Dement Geriatr Cogn Dis Extra. 2013 Sep 28;3(1):320-32
pubmed: 24174927
Ann Neurol. 1999 Dec;46(6):933
pubmed: 10589550
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Am J Psychiatry. 1999 Apr;156(4):564-8
pubmed: 10200735
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Dev Neurobiol. 2019 Jul;79(7):750-766
pubmed: 31379087
Arch Neurol. 1999 Mar;56(3):303-8
pubmed: 10190820
Alzheimers Dement. 2011 May;7(3):257-62
pubmed: 21514247
J Intellect Disabil Res. 2017 Sep;61(9):843-852
pubmed: 28664561
Neurobiol Aging. 2012 Sep;33(9):1988-94
pubmed: 21958962
Sci Rep. 2018 May 30;8(1):8431
pubmed: 29849029
Lancet. 2020 Jun 27;395(10242):1988-1997
pubmed: 32593336
PLoS One. 2017 Nov 30;12(11):e0188802
pubmed: 29190730
J Neurosci. 2007 Jun 6;27(23):6174-84
pubmed: 17553989
Nat Med. 1996 Jan;2(1):93-5
pubmed: 8564851
Alzheimers Res Ther. 2019 Mar 21;11(1):26
pubmed: 30902060
Ann Clin Transl Neurol. 2018 May 20;5(6):741-751
pubmed: 29928657
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Front Behav Neurosci. 2015 Sep 14;9:239
pubmed: 26441570
J Intellect Disabil Res. 2014 Jan;58(1):61-70
pubmed: 23902161
J Alzheimers Dis. 2017;56(2):459-470
pubmed: 27983553
Nat Rev Dis Primers. 2020 Feb 6;6(1):9
pubmed: 32029743
Alzheimers Dement. 2012 Nov;8(6):496-501
pubmed: 23102120
Neurology. 2010 Nov 2;75(18):1639-44
pubmed: 21041786
Curr Opin Psychiatry. 2017 Mar;30(2):102-107
pubmed: 28009725
Neuron. 2014 Nov 5;84(3):608-22
pubmed: 25442939
Neurology. 2016 Sep 20;87(12):1235-41
pubmed: 27558378
Am J Ment Retard. 2008 Sep;113(5):369-86
pubmed: 18702557
Mayo Clin Proc. 2013 Aug;88(8):831-40
pubmed: 23849993
Alzheimers Dement. 2018 Apr;14(4):563-575
pubmed: 29653607
Neurobiol Aging. 2019 Dec;84:70-79
pubmed: 31518951
Brain. 2014 Sep;137(Pt 9):2556-63
pubmed: 24993958
Neurology. 1988 Jun;38(6):938-42
pubmed: 2966900
Alzheimer Dis Assoc Disord. 2009 Oct-Dec;23(4):315-8
pubmed: 19571732
J Intellect Disabil Res. 2007 Jun;51(Pt. 6):463-77
pubmed: 17493029
Neurology. 2001 Apr 10;56(7):979-80
pubmed: 11294944
CNS Drugs. 2016 Jul;30(7):567-73
pubmed: 27272473
J Alzheimers Dis. 2019;70(1):131-138
pubmed: 31156181
Neurosci Lett. 2003 May 22;342(3):155-8
pubmed: 12757888
BMB Rep. 2009 Jan 31;42(1):6-15
pubmed: 19192387
Br J Psychiatry. 2018 Nov;213(5):668-669
pubmed: 30339114
Am J Psychiatry. 2002 Jan;159(1):74-81
pubmed: 11772693
Am J Psychiatry. 2003 Oct;160(10):1870-8
pubmed: 14514503
Am J Intellect Dev Disabil. 2020 Mar;125(2):97-99
pubmed: 32058812
Alzheimers Res Ther. 2014 Sep 12;6(5-8):60
pubmed: 25478025
N Engl J Med. 1989 Jun 1;320(22):1446-52
pubmed: 2566117
Alzheimers Res Ther. 2018 Apr 10;10(1):39
pubmed: 29631614
J Alzheimers Dis. 2018;61(2):717-728
pubmed: 29226868
Nature. 2018 Feb 8;554(7691):249-254
pubmed: 29420472
Front Aging Neurosci. 2017 Jan 17;8:316
pubmed: 28144219
Neurol Ther. 2017 Jul;6(Suppl 1):69-81
pubmed: 28733957
J Alzheimers Dis. 2017;60(2):439-450
pubmed: 28946567
Neurology. 2018 May 8;90(19):e1682-e1691
pubmed: 29653987
J Neurodev Disord. 2019 Dec 16;11(1):39
pubmed: 31842726
Dev Neurobiol. 2019 Jul;79(7):684-698
pubmed: 31389176
Neurobiol Aging. 2017 Oct;58:68-76
pubmed: 28715661
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Healthcare (Basel). 2018 Aug 25;6(3):
pubmed: 30149606
Lancet Neurol. 2016 May;15(6):622-36
pubmed: 27302127
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494
ACS Chem Neurosci. 2020 Jan 15;11(2):191-196
pubmed: 31799825
Alzheimers Dement. 2019 Feb;15(2):245-257
pubmed: 30503169
Neurodegener Dis Manag. 2015;5(3):249-56
pubmed: 26107323
Alzheimers Dement (N Y). 2016 Jun;2(2):69-81
pubmed: 28642933
Neurosci Lett. 2001 Apr 6;301(3):199-203
pubmed: 11257432
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248